Key points are not available for this paper at this time.
Background Non-metastatic castration-resistant prostate cancer (nmCRPC) patients are often older and use concurrent medications that increase potential for drug-drug interactions (pDDIs). This study assessed pDDI prevalence in real-world nmCRPC patients treated with apalutamide, darolutamide, or enzalutamide.
Appukkuttan et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: